Skip to search formSkip to main contentSkip to account menu

DI17E6

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized

Narrower (1)

EMD 525797

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Primary outcomes of the placebo-controlled phase 2 study PERSEUS (NCT01360840) investigating two dose regimens of abituzumab (DI17E6, EMD 525797) in the treatment of chemotherapy-naive patients (pts…
5030 Background: The humanized monoclonal IgG2 antibody abituzumab inhibits αv integrins expressed on CRPC cells, tumor vessels… 
2014
2014
Abstract 857: Preclinical evaluation: efficacy of DI17E6, a therapeutic antibody against alpha v integrins, compared to cilengitide in sensitizing human cancers to radiation therapy
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Purpose: Integrins are implicated in resistance of solid… 
2012
2012
Final analysis: A multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer with bone metastases…
231 Background: EMD 525797 is a humanized monoclonal IgG2 antibody specifically targeting αv integrins involved in tumor… 
2012
2012
Phase I study of EMD 525797 (DI17E6), an antibody targeting ανβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic…
3539 Background: EMD 525797 is a humanized monoclonal antibody that specifically targets all αν integrins, including ανβ1, ανβ3… 
2012
2012
Final analysis: A multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer with bone metastases…
231 Background: EMD 525797 is a humanized monoclonal IgG2 antibody specifically targeting αv integrins involved in tumor… 
2011
2011
A multicenter phase I study of DI17E6, a novel de-immunized monoclonal antibody to human αv integrins, in progressive castrate-resistant prostate cancer (CRPC) with bone metastases after chemotherapy…
e15060 Background: Integrins are cell surface receptors contributing to tumor progression by increasing cell migration, invasion… 
2011
2011
7013 POSTER DISCUSSION A Phase 1 Study of DI17E6, an Antibody Targeting AV Integrins, in Progressive Castrate-resistant Prostate Cancer With Bone Metastases (mCRPC) After Chemotherapy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)